schizophrenia

Researchers eye genetic factors in schizophrenia drugs

By GREGORY ZELLER // A new study by Feinstein Institute for Medical Research scientists suggests that a patient’s response to antipsychotic pharmaceuticals can be predicted by genetic predispositions. Schizophrenia – characterized by delusions, hallucinations and disorganized thoughts – is one of the leading causes of disability in the United States. Antipsychotic pharmaceuticals are a common treatment option, but such therapies are often “given without guidance from lab tests to show effectiveness, as is common in…


Researchers zoom in on schizophrenia biomarkers

A Feinstein Institute for Medical Research scientist will focus next-level imaging techniques on schizophrenia and other brain disorders, thanks to a hefty federal grant. Research scientist Anil Malhotra – a professor in the Feinstein Institute’s Center for Psychiatric Neuroscience and the Hofstra Northwell School of Medicine’s Department of Molecular Medicine – has been awarded a five-year, $3 million R01 grant from the National Institutes of Health to identify biomarkers specific to schizophrenia and treatment-resistant psychosis. The biomarkers…


A giant step on the road to precision medicine

By GREGORY ZELLER // This is your brain. This is your brain on antipsychotic medications. Any questions? Investigators at the Feinstein Institute for Medical Research, the R&D wing of the North Shore-LIJ Health System, have plenty. Among them: Can doctors use brain scans to predict how patients will respond to antipsychotic medications – even before medications are prescribed? Such predictability would allow providers to fine-tune prescribed meds and doses, a potentially enormous innovation in the…